相关实验视频

Updated: May 24, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

工程长寿命的电荷分离状态增强了I型ROS的产生,以实现高效的癌症治疗

Zhongyan Hu¹, Wenjing Liu², Jianyu Zhang³

¹College of Chemistry, Chemical Engineering and Materials Science, Shandong Normal University, Jinan, 250014, China; Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chemical Biology Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing, 401331, China.

|March 3, 2025

概括

一种新的有机光敏感剂MTPAA可以提高I型反应性氧物种 (ROS) 的产生超过8倍. 这种"甲基效应"提高了低氧瘤的光动力疗法疗效,克服了氧气耗尽的挑战.

科学领域:

摄影化学的使用.
有机化学有机化学
光动力学疗法光动力学疗法

背景情况:

有机光敏感剂 (PSs) 具有长寿命的电荷分离状态 (CSs),通过产生反应性氧物种 (ROS) 对光动力疗法 (PDT) 至关重要.
固体瘤往往表现出缺氧,这限制了依赖单片氧 (II型ROS) 的PDT的有效性,这是由于氧气消耗.

研究的目的:

开发一种新的有机光敏感剂,增强I型ROS生成,克服PDT中缺氧诱导的局限性.
在低氧条件下研究酸盐的结构改造,以提高它们在低氧条件下的抗癌功效.

主要方法:

通过添加甲基替代的二胺基组来生成MTPAA.Fukuzumi基盐的结构修改.
通过与非甲基化类似物 (TPAA) 的比较研究评估I型ROS发电效率.
在体外细胞实验中,评估在低氧条件下MTPAA光动力疗法的疗效.

主要成果:

与TPAA相比,MTPAA的I型ROS生成量增加了8倍以上,这归因于通过共振稳定激进物种的"甲基效应".
细胞实验证实,MTPAA显著提高光动力学治疗的疗效,即使在低氧环境中.
分子设计策略有效地解决了固体瘤中氧气耗尽的挑战.

结论:

开发的MTPAA光敏感剂显示增强了I型ROS生成,并改善了缺氧下的PDT疗效.
"甲基效应"是稳定激进物种和促进ROS产生的关键因素.
这种合理的分子设计策略为开发用于癌症治疗的高性能I型光敏剂提供了有希望的途径.

关键词:

聚合引发的排放量聚合引发的排放量氧气过低是因为缺氧.长寿命的电荷分离器长寿命的电荷分离器甲基效应是指甲基效应.光动力学疗法是一种光动力学疗法.

更多相关视频

Author Spotlight: High-Throughput Measurement of Intracellular ROS Levels in Hepatocellular Lines

Author Spotlight: High-Throughput Measurement of Intracellular ROS Levels in Hepatocellular Lines

Published on: January 19, 2024

Production and Detection of Reactive Oxygen Species ROS in Cancers

Production and Detection of Reactive Oxygen Species ROS in Cancers

Published on: November 21, 2011

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...